Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects.

Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” second-quarter ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.

Tempus AI is a growth stock that is down 31% from all-time highs. Here's why TEM AI stock could be a part of your TFSA ...

Tempus AI, Inc. (NASDAQ:TEM) is one of the stocks on Jim Cramer’s radar. Answering a caller’s query about the company during the lightning round, Cramer said: “Okay, another company that’s just losing ...

Former House Speaker Nancy Pelosi said back in 2022 the Senate would soon vote on a bill banning members of Congress from trading individual stocks. Roughly three years later, Pelosi is no ...

Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...

This marks the second FDA-cleared ECG-AI device in Tempus’ cardiovascular product suite, following its previously cleared Tempus ECG-AF solution. The new software analyzes resting, non-ambulatory ...

TEM Price Action: Tempus stock is up 3.9% to $60.68 on Thursday versus a 52-week trading range of $31.36 to $91.45. Tempus stock is up 70% year-to-date in 2025.